Get the Stockscreener App
1.42
5.33%
-0.08
Pre-market:
1.42
Hoth Therapeutics Inc stock is traded at $1.42, with a volume of 2.09M.
It is down -5.33% in the last 24 hours and up +75.31% over the past month.
Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.
See More
Previous Close:
$1.50
Open:
$1.5
24h Volume:
2.09M
Relative Volume:
0.24
Market Cap:
$9.80M
Revenue:
-
Net Income/Loss:
$-9.62M
P/E Ratio:
-0.2977
EPS:
-4.77
Net Cash Flow:
$-7.93M
1W Performance:
-8.39%
1M Performance:
+75.31%
6M Performance:
+72.71%
1Y Performance:
+10.08%
1-Day Range:
$1.36
$1.55
1-Week Range:
$1.36
$1.7099
52-Week Range:
$0.58
$3.80
Hoth Therapeutics Inc Stock (HOTH) Company Profile
Name
Hoth Therapeutics Inc
Sector
Industry
Phone
(646)756-2997
Address
590 MADISON AVENUE, NEW YORK, NY
Compare HOTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOTH
Hoth Therapeutics Inc
|
1.42 | 9.80M | 0 | -9.62M | -7.93M | -4.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-19 | Initiated | The Benchmark Company | Speculative Buy |
Hoth Therapeutics Inc Stock (HOTH) Latest News
HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal - MSN
Hoth Therapeutics expands cancer drug patent portfolio - MSN
Hoth Therapeutics Acquires New Patent Applications - Contract Pharma
Hoth Therapeutics Expands Cancer Drug Patent Portfolio, Strengthens HT-001 Development Strategy - StockTitan
Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025 - PR Newswire
Hoth Therapeutics’ (HOTH) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More - MSN
Shares Of This Micro Cap More Than Doubled Today - MSN
3 Penny Stocks to Watch Now, 1/9/25 - TipRanks
Hoth Therapeutics maintains strong cash position, no offering plans By Investing.com - Investing.com Nigeria
Hoth Therapeutics Shares Recover; Company Has No Plans for Offering - MarketWatch
Hoth Therapeutics maintains strong cash position, no offering plans - Investing.com
Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries - PR Newswire
S&P 500 E-Mini (ESM23) Quote - The Globe and Mail
Hoth Therapeutics’ Stock Triples On Promising Cancer Trial Data for Skin Toxicity Therapy: Retail’s Excited - Asianet Newsable
Dow Jones Transportations Average (DOWT) QuotePress Release - The Globe and Mail
Dow Jones Global (DOWG) QuotePress Release - The Globe and Mail
Hoth reports 100% success in cancer skin toxicity trial By Investing.com - Investing.com South Africa
Hoth Therapeutics up over 218% on dermatology breakthrough for cancer patients - Mugglehead
Hoth Therapeutics stock hits 52-week high at $1.73 By Investing.com - Investing.com Australia
S&P 500 ESG (ESG) QuotePress Release - The Globe and Mail
PHLX Euro FX (XDE) QuotePress Release - The Globe and Mail
TSX Composite Low Volatility (TXLV) QuotePress Release - The Globe and Mail
Hoth Therapeutics Soars 215% on Breakthrough Cancer Treatment Success - Yahoo Finance
Why Hoth Therapeutics Inc Stock Might Make Sense If Bought Today - Stocks Register
Stock market news: Hoth Therapeutics +184.32%, DatChat +79.85% among top gainers during mid day trading - Business Upturn
Stock market news: SPI Energy saw rise of 276.74% while Hoth Therapeutics surged by 186.73% during mid day trading - Business Upturn
Nasdaq Down 1.5%; RPM Posts Upbeat Results - Benzinga
Hoth’s phase IIa derma data in cancer patients propels its stock - BioWorld Online
Why Is Hoth Therapeutics Stock Flying Higher On Tuesday? - Benzinga
Hoth Therapeutics Shares Hit 52-Week High on Positive Data for Cancer Treatment - MarketWatch
Stock market today: XTI Aerospace surged by 108.52% while ACELYRIN posted fall of 38.68% in early trading - Business Upturn
Dow Surges Over 100 Points; US Trade Deficit Widens In November - Benzinga
Hoth Therapeutics stock hits 52-week high at $1.73 - Investing.com
Hoth reports 100% success in cancer skin toxicity trial - Investing.com
Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities - PR Newswire
Cero Therapeutics to effect 1-for-100 reverse stock split - Yahoo Finance
VA Enters Into Development Partnership with Hoth Therapeutics - The Presidential Prayer Team
Viking Therapeutics, Inc. (VKTX) Advances While Market Declines: Some Information for Investors - Yahoo Finance
Hoth acquires license to technology developed by the VA and Emory University - BioWorld Online
Hoth licenses patents to develop anti-obesity treatments - MSN
EGFR Inhibitors-Induced Skin Disorders Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Lutris Pharma, Hoth Therapeutics, TWi Biotechnology - Barchart
Hoth Therapeutics Enters Partnership with the Department of Veterans Affairs to Develop Obesity Treatment - Longview News-Journal
Is Sarepta Therapeutics, Inc. (SRPT) the Best Performing Biotech Stock in 2024? - Yahoo Finance
Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial - The Eastern Progress Online
Hoth Therapeutics Inc Stock (HOTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):